Boldenone undecylenate (commonly known as Equipoise or EQ) is a derivative of testosterone, exhibiting a similar androgenic activity but with enhanced mytrophic activity. Notably, Boldenone undecylenate undergoes minimal conversion to estrogen, thereby mitigating the risk of estrogen-related side effects. Instead, it is metabolized by 5-alpha-reductase into dihydroboldenone, through which some of its androgenic effects are mediated.
This compound is valued for its ability to heighten the body's overall metabolism rate and stimulate appetite. Its primary objective is to elevate red blood cell count while fostering lean body mass development. Due to its favorable side effect profile, Boldenone undecylenate serves as a therapeutic option for competitive athletes, bodybuilders, and individuals affected by age-related non-genomic muscle degenerative conditions like sarcopenia.
The undecylenate ester extends the half-life of Boldenone in the bloodstream, allowing for a sustained release over approximately 10 days, depending on the dosage administered.
 
Packaging: Single vial with silicone stopper, containing 10ml of product.
Dosage & administration:
Half life
12 days
Adult dose (Male)
300mg-900mg EOD, ETD, EFD intramuscular injection.
Adult dose (Female)
25mg-100mg EOD, ETD, EFD intramuscular injection.
Average Cycle Length
4-12weeks following an EOD, ETD or EFD injection pattern
Anabolic #
100
Androgenic #
50
Bioavailability
Estimated at 100%
CAS Name
1,4-androstadiene-3-one,17-ol
Synonyms
EQ, Equipoise, Bold, Boldenone